Stereotactic radiosurgery for brainstem metastases: Survival, tumor control, and patient outcomes.
OBJECTIVE
Patients with brainstem metastases have limited treatment options. In this study, we reviewed outcomes after stereotactic radiosurgery (SRS) in the management of patients with brainstem metastases.


METHODS
Records were reviewed of 22 consecutive patients presenting with brainstem metastases who underwent SRS. The most frequent primary malignancy was the lung (n = 11), followed by breast (n = 3) and kidney (n = 2). Three patients (14%) also underwent whole-brain radiation therapy (WBRT). The median tumor volume was 0.9 mL (range, 0.1-3.3 mL); the median tumor margin dose was 16 Gy (range, 14-23 Gy).


RESULTS
Median survival time after SRS was 8.5 months. Although local tumor control was achieved in all patients with imaging follow-up (n = 19), 5 patients died from development and progression of new brain metastases. Two patients (9%) had symptom improvement after SRS, whereas 1 patient (5%) developed a new hemiparesis after SRS.


CONCLUSIONS
Radiosurgery is safe and provides a high local tumor control rate for patients with small brainstem metastases. Patients with limited systemic disease and good performance status should be strongly considered for SRS.
Hussain
Aamir
A
Department of Radiation Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Brown
Paul D
PD
Stafford
Scott L
SL
Pollock
Bruce E
BE
D000328:Adult; D000368:Aged; D020295:Brain Stem Neoplasms / Q000532:radiotherapy*; D001943:Breast Neoplasms; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms; D008175:Lung Neoplasms; D008297:Male; D008875:Middle Aged; D016634:Radiosurgery / Q000379:methods*; D016896:Treatment Outcome